A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia

Trial Profile

A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Dec 2017

At a glance

  • Drugs Camidanlumab tesirine (Primary)
  • Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Sponsors ADC Therapeutics
  • Most Recent Events

    • 12 Dec 2017 Interim results (n=29; data cut off: 26 Jun, 2017) assessing tolerability and safety, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 11 Dec 2017 Interim results (n=33) published in the ADC Therapeutics media release.
    • 11 Dec 2017 According to an ADC Therapeutics media release, data from this trial was presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition (2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top